Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
104 hedge funds and large institutions have $489M invested in Aerie Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 51 increasing their positions, 25 reducing their positions, and 10 closing their positions.
661% more call options, than puts
Call options by funds: $4.92M | Put options by funds: $647K
104% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 25
52% more capital invested
Capital invested by funds: $322M → $489M (+$167M)
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
2% more funds holding
Funds holding: 102 → 104 (+2)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$6.28M |
| 2 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$3.07M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.77M |
| 4 |
SCM
Suffolk Capital Management
New York
|
+$1.93M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$2.19M |
| 2 |
SIM
Spark Investment Management
New York
|
-$1.97M |
| 3 |
DM
Deerfield Management
New York
|
-$1.81M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.38M |
| 5 |
CCI
Columbus Circle Investors
|
-$1.06M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
101
IFP Advisors
Tampa,
Florida
| $7K | +$6.47K | +400 | New |
|
102
JP Morgan Chase
New York
| $5K | -$5.05K | -312 | -52% |
|
|
MCM
103
Manchester Capital Management
Manchester,
Vermont
| $3K | – | – | – |
|
|
SIM
104
Spark Investment Management
New York
| – | -$1.97M | -161,900 | Closed |
|
|
105
Invesco
Atlanta,
Georgia
| – | -$1.38M | -113,198 | Closed |
|
106
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$570K | -46,889 | Closed |
|
107
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$306K | -18,915 | Closed |
|
108
Citadel Advisors
Miami,
Florida
| – | -$209K | -12,917 | Closed |
|
|
FO
109
FT Options
Chicago,
Illinois
| – | -$153K | -12,614 | Closed |
|
|
QT
110
Quantbot Technologies
New York
| – | -$115K | -9,530 | Closed |
|
111
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$12K | -998 | Closed |
|
|
TRCT
112
Tower Research Capital (TRC)
New York
| – | -$12K | -951 | Closed |
|
113
Bessemer Group
Woodbridge,
New Jersey
| – | -$1K | -54 | Closed |
|
114
SEI Investments
Oaks,
Pennsylvania
| – | +$453 | +28 | +2,800% |
|
AERI Hedge Fund Activity: Q2 2016 in Review
104 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q2 2016, worth a combined $489M — up 52% from $322M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AERI positions and 10 closed out — a net gain of 2 holders — while 51 added to existing stakes and 25 trimmed.
The largest buyer was Foresite Capital Management III, adding an estimated $6.28M. The largest seller was A.R.T. Advisors, cutting an estimated $2.19M.
- 104 institutional investors held Aerie Pharmaceuticals (AERI) as of Q2 2016, up from 102 in Q1 2016.
- Funds reported $489M of Aerie Pharmaceuticals stock for Q2 2016, up 52% quarter-over-quarter.
- 12 funds opened new Aerie Pharmaceuticals positions in Q2 2016 and 10 closed out, a net change of +2 holders.
- The largest Aerie Pharmaceuticals buyer in Q2 2016 was Foresite Capital Management III, an estimated $6.28M added.
- The largest Aerie Pharmaceuticals seller in Q2 2016 was A.R.T. Advisors, an estimated $2.19M sold.
Based on aggregated 13F filings for Q2 2016.